Despite rigorous implementation and optimal dosing of guideline-directed medical therapy, a subset of patients with heart failure (HF) remain at high residual risk for complications. This vulnerable group of patients may benefit from a multi-modality approach, consisting of treatment options with different mechanisms of action to help prevent hospitalizations and reduce cardiovascular mortality.
In this symposium, experts discuss current and emerging treatment options for the prevention and treatment of HF, across a spectrum of ejection fractions.
President of the Baylor Scott and White Research Institute
Maxwell A. and Gayle H. Clampitt Endowed Chair
Dallas, Texas
Distinguished Professor of Medicine
University of Mississippi
Jackson, Mississippi
Edward D. Frohlich Distinguished Chair
Professor of Medicine
Harvard Medical School
Brigham and Women's Hospital
Boston, Massachusetts
Professor of Medicine
Director, Preventive Cardiology
Associate Director, Barbra Streisand Women’s Heart Center
Anita D. Friedman Chair in Cardiovascular Medicine & Research
Smidt Heart Institute at Cedars Sinai Medical Center
Los Angeles, California
11:00 am
Welcome and Introductions
11:05 am
State of the State – Preventing and Treating HF Today
11:20 am
Implementing the Latest Guideline Recommendations for HF Prevention and Treatment
11:35 am
Focus on MRAs for HF – Past, Present, and Future
11:45 am
Conclusion and Q&A
In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Medscape, LLC designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Medscape designates this continuing education activity for 1.0 contact hour(s) (0.100 CEUs) (Universal Activity Number: JA0007105-0000-24-224-L01-P).
Upon completion of this activity, participants will:
Have increased knowledge regarding the:
- New therapeutic options to prevent/treat HF
- Latest guideline recommendations for HF prevention and treatment
- Role of mineralocorticoid receptor antagonists (MRAs) in the prevention and treatment of HF
- Mechanism of action of MRAs, including key differentiators between nonsteroidal MRAs (nsMRAs) and steroidal MRAs (sMRAs)
- Evolving clinical trial evidence for nsMRA in the setting of HF
The goal of this activity is for learners to be better able to evaluate emerging treatment strategies for the treatment of HF.
This activity is intended for cardiologists, primary care physicians, nephrologists, nurses, and pharmacists.
This educational activity is presented through a collaboration between Medscape Cardiology and the Heart Failure Society of America. The program topic, learning objectives, and faculty have been reviewed and approved by HFSA.